Inclusion Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Diagnosis of metastatic ocular melanoma Progressive disease
Measurable disease HLA-A*201 positive --Prior/Concurrent Therapy-- Biologic therapy: At
least 3 weeks since prior biologic therapy Chemotherapy: At least 3 weeks since prior
chemotherapy Endocrine therapy: At least 3 weeks since prior endocrine therapy No
concurrent steroid therapy Radiotherapy: At least 3 weeks since prior radiotherapy
Surgery: Not specified --Patient Characteristics-- Age: 16 and over Performance status:
ECOG 0-2 Life expectancy: More than 3 months Hematopoietic: WBC at least 3,000/mm3
Platelet count at least 90,000/mm3 No coagulation disorders Hepatic: Bilirubin no greater
than 2.0 mg/dL AST/ALT less than 3 times normal Hepatitis B surface antigen negative
Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No major cardiovascular
illness For interleukin-2 (IL-2) therapy: No cardiac ischemia No myocardial infarction No
cardiac arrhythmias Pulmonary: No major respiratory system illness For IL-2 therapy: No
obstructive or restrictive pulmonary disease Other: Not pregnant or nursing Negative
pregnancy test Fertile patients must use effective contraception No active systemic
infection No autoimmune disease No primary or secondary immunodeficiency by abnormal
lymphocyte counts or presence of opportunistic infection